Highlights GlobeImmune, Inc.

Equities

GBIM

US37957B1008

Market Closed - OTC Markets Other stock markets 18:43:20 14/03/2024 GMT			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-.--%

2022	Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital announced an offer to acquire 12.2% stake in GlobeImmune, Inc. for $7,000.	CI
2017	NantCell, Inc. Exercises Option for Licensing Agreement with GlobeImmune, Inc. for GI-6100	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital announced an offer to acquire 12.2% stake in GlobeImmune, Inc. for $7,000.	05/05/22	CI
NantCell, Inc. Exercises Option for Licensing Agreement with GlobeImmune, Inc. for GI-6100	30/08/17	CI
NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-4000	30/08/17	CI
NantCell, Inc. Enters into Licensing Agreement with GlobeImmune, Inc. for GI-6207 and GI-6301	30/08/17	CI
Gilead Sciences, Inc. Terminates the Collaboration and License Agreement with GlobeImmune	17/11/16	CI
Globeimmune, Inc Announces Financial Results for the First Quarter Ended March 31, 2016	12/05/16	CI
GlobeImmune Inc. Reports Earnings Results for the Year Ended December 31, 2015; Provides Update on Clinical Programs	16/03/16	CI
GlobeImmune Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	13/11/15	CI
GlobeImmune Inc. Announces Earnings Results for the Second Quarter Ended June 30, 2015	14/08/15	CI
Globeimmune, Inc. Enters into License Agreement with Celgene Corporation	04/08/15	CI
GlobeImmune, Inc. Announces Line Results from GS-4774 Phase 2 Trial in Virally-Suppressed Chronic HBV Patients	27/05/15	CI
GlobeImmune Inc. Announces Opening of Randomized Phase 2 Chordoma Trial at National Cancer Institute	22/04/15	CI
Globeimmune, Inc. Provides Update on Business and Clinical Programs; Reports Earnings Results for the Year Ended December 31, 2014	17/03/15	CI
GlobeImmune Inc. Announces Earnings Results for the Quarter and Nine Months Ended September 30, 2014	12/11/14	CI
Globeimmune Announce Updated Results from Eleven Chordoma Patients in the GI-6301 Phase 1 Trial	17/10/14	CI
GlobeImmune Inc. Announces Financial Results for the Second Quarter and Six Months Ended June 30, 2014	15/08/14	CI
GlobeImmune, Inc. has completed an IPO in the amount of $15 million.	01/07/14	CI
GlobeImmune, Inc. has filed an IPO in the amount of $35 million.	14/03/14	CI
GlobeImmune, Inc. has withdrawn its IPO in the amount of $65 million.	30/10/13	CI
GlobeImmune, Inc. Announces Presentation of GI-4000 Phase 2 Data at IASLC World Conference on Lung Cancer	27/10/13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights GlobeImmune, Inc.

Equities

GBIM

US37957B1008

Highlights

Filters